Navigation Links
Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:4/26/2008

redictive value, PPV) than patients in the Pegasys combination arm (92 vs. 87 vs. 80 percent, and 81 vs. 83 vs. 74 percent, respectively).(5)

-- Relapse after the end of treatment was lower for patients in the PEGINTRON combination therapy arms compared to patients receiving Pegasys and Copegus (24 vs. 20 vs. 32 percent, respectively). In a multivariate logistic regression analysis, among the factors significantly affecting relapse were: baseline viral load greater than 600,000 IU/mL vs. less than or equal to 600,000 IU/mL (p-value less than 0.001); age greater than 40 vs. less than or equal to 40 (p-value less than 0.001); fibrosis F3/4 vs. F0/1/2 (p-value equal to 0.001); Pegasys regimen vs. PEGINTRON 1.0 mcg regimen (p-value less than 0.001); glucose fasting greater than or equal to 5.6 vs. less than 5.6 (p-value equal to 0.002); steatosis 0 percent vs. greater than 0 percent (p-value equal to 0.002); ALT normal vs. elevated (p-value equal to 0.008); and Pegasys regimen vs. PEGINTRON 1.5 mcg regimen (p-value equal to 0.012).

-- End of treatment response was higher in the Pegasys combination arm (53 vs. 49 vs. 64 percent, respectively).

-- Ribavirin dose: One of the key questions of the study has been whether the protocol-assigned ribavirin dose regimen or the protocol-specified dose reduction schedule disadvantaged patients in any of the treatment arms, particularly in the Pegasys combination arm. However, the final results of IDEAL showed that the majority of patients in the Pegasys therapy arm received a higher ribavirin dose over the duration of the study, including patients with ribavirin dose reductions or discontinuations, based on the actual median ribavirin dose received (mg/kg/day), regardless of treatment outcome (SVR, relapsers and nonresponders) [p-value less than 0.001 for ribavirin dose received in the PEGINTRON 1.5 mcg arm vs. Pegasys arm and p-value less than or equal to 0.001 for ribavirin dose received in the PEGINTRON 1.0 a
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
3. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
4. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
11. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015 Pharma Major ... in ZAO "Biocom" in Russia subject ... the Russian pharmaceutical market which recorded RUB 765 billion in ... markets in the world in 2014 (IMS Health). For over ... expected to continue with this trend, projecting Russia ...
(Date:7/2/2015)... DURHAM, N.C. , July 2, 2015 ... its acquisition of assets related to the ion channel ... that had previously been obtained as part of Pfizer,s ... all of Pfizer,s rights to the "Icagen" name and ... will provide comprehensive services for ion channel and transporter ...
(Date:7/2/2015)... 25, 2015 ... the addition of the "2015 New ... Challenges, Emerging Technologies, Competitive Landscape" report ... Frontiers in Clinical Chemistry and Immunodiagnostics: Global ... new seven-country strategic analysis of major business ...
Breaking Medicine Technology:Lupin Acquires Biocom in Russia 2Lupin Acquires Biocom in Russia 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2
... CareFusion (NYSE: CFN ), a leading, ... launch of the AVA max® Vertebral Balloon, a ... for treating spinal compression fractures.   The ... and is expected to enhance the affordability of spinal ...
... Mass., Aug. 26 Sermo ... physicians, today announced a free Sermo Report titled, " ... covers physician opinions about the introduction of an investigational ... to the results, 46% of physicians feel that ticagrelor ...
Cached Medicine Technology:CareFusion Announces National Launch of Spinal Fracture Device 2CareFusion Announces National Launch of Spinal Fracture Device 3Sermo Report Indicates that Ticagrelor is Likely to Affect the Standard of Care for ACS Patients 2
(Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to ... the 19th sweetFrog store located in the Lone Star State. The premium frozen yogurt ... in 2014. , The store, which opened July 1 at Duke’s Travel Plaza, is ...
(Date:7/2/2015)... ... ... With summer in full swing, Americans are flocking to Canada’s many lakes to reel in ... in the world, and it’s easy to understand why. From the Pacific Northwest Coast of ... Recreational fishing is a huge industry, and Americans make up the vast majority of anglers ...
(Date:7/2/2015)... PEACHTREE CITY, GA (PRWEB) , ... July 02, 2015 , ... ... introduce their newest innovation in compression socks designed for men. , For style ... compression socks into their daily routine. This is great news for men everywhere because ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... 2015” provides comprehensive information on the pipeline products with comparative analysis of ... wound therapy (NPWT) with 22 market data tables and 4 figures, spread ...
(Date:7/2/2015)... ... July 02, 2015 , ... Breakthrough ... wrist pain treatment. Dr. Lev Kalika, founder of New York Dynamic Neuromuscular ... authority on the conservative treatment of back, hip, knee and shoulder pain as ...
Breaking Medicine News(10 mins):Health News:sweetFrog Expands Texas Footprint with Location in Canton 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 2Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 3Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 4
... may not only be healthy to the body but also ... that consuming milk, water, fruits and vegetables worsened the taste ... taste, according to the scientists. ,The findings ... of a gum or lozenge that makes cigarettes less palatable, ...
... the US has pledged to spend over 500 million US ... . ,The announcement by the Robert Wood Johnson ... health initiatives ever tried by private philanthropy. ... country in terms of morbidity and mortality and economically,” said ...
... peppers have been credited with mysterious medicinal properties due ... history, hot peppers have been used to fight topical ... tasty heat generators are also being used to treat ... the main chemical found in hot peppers, there are ...
... has assured assistance to doctors of Indian origin who are ... in London due to changes in immigration rules. // ... changes that make it difficult for non-European Union doctors to ... April 2006, and have since been the subject of litigation. ...
... Haryana government Tuesday proposed a medical university in the state ... ,Addressing the silver jubilee celebrations of the Government Dental ... Hooda said that setting up a medical university would help ... ,Hooda said that paucity of funds would ...
... test that can tell if a person is in dire ... , Duke University researchers led by John Chute, suggest that ... scan thousands of genes in the DNA of lymphocytes could ... ,Says Chute: "The goal would be to ...
Cached Medicine News:Health News:Diet May Play Vital Role to Help Smokers Quit 2Health News:500 Million US Dollars to Fight Childhood Obesity 2Health News:Spicy Pepper Remedy Equalizes Spring Pollen Allergies 2Health News:India Assures Help to Doctors of Indian Origin 2Health News:Gene Study To Reveal Radiation Poisoning 2
... Achieve high-speed productivity in the lab ... system, dedicated for pre- and post-analytical sorting ... HSS selectively decaps and then sorts primary ... to save time, labor, and eliminate ...
... Catering to the special needs ... Infant ThermoWrap™ protects the littlest ... their most vulnerable by providing ... continuous management of an infants ...
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
A smaller version of the Model 525 lower body blanket, this blanket is ideal for warming the large child or small adult during upper body surgery....
Medicine Products: